What should the Investigational Brochure describe regarding risks and monitoring?

• A. Description of possible risks and adverse drug reactions and precautions or monitoring
• B. Marketing approval status and country registrations
• C. Production quotas
• D. Environmental impact

Answer: (A)

The essential idea is that investigators must have a clear, safety-focused overview of what could happen with the investigational product and how to watch for it. The Investigational Brochure should describe the possible risks and adverse drug reactions, covering what events might occur, how severe they could be, how reversible they are, and any factors that might raise risk. It also lays out the precautions and the monitoring plan—what safety assessments to perform, how often, which tests or measurements to track, how adverse events and serious adverse events should be detected and reported, and what actions to take (stopping rules or dose adjustments) if safety concerns arise. This safety and monitoring information supports informed consent and ongoing risk management during the trial. Information about marketing approval status, country registrations, production quotas, or environmental impact is not the focus of the Investigational Brochure.